Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PANCAID

Financiado

PANcreatic CAncer Initial Detection via liquid biopsy

Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological adv... ver más

31/12/2027

UKE

10M€

Presupuesto del proyecto: 10M€

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 20 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-02

HORIZON-MISS-2021-CANCER-02-01: Develop new methods and technologie... ExpectedOutcome:Prevention is the most cost-effective long-term cancer control strategy. In EU-27 an...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

20 Participantes

UKE

2.11M€ | Lider

FUNDACION SECTOR PUBLICO EST...

864.25K€ | Participante

MACCABI HEALTHCARE SERVICES...

250.75K€ | Participante

THE CHANCELLOR MASTERS AND S...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ColoDix Disruptive and high accuracy test for early colorectal cance... 4M€ Cerrado

PID2020-120306RB-I00 INTEGRAL STAGING, PROGNOSTIC AND DIAGNOSTIC OF CANCER IN LIQ... 184K€ Cerrado

CPP2021-008897 Solución de biopsia líquida para el diagnóstico precoz del c... 157K€ Cerrado

FG_WIT AUTOMATED PROTOTYPE OF CANCER DETECTION FROM CTDNA 75K€ Cerrado

PLEC2021-007892 Plataforma (Oncodeeplasm) para inmunoensayos optoplasmónicos... 336K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2022-12-02
Fecha Fin: 2027-12-31

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 10M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological advances in Liquid Biopsy Diagnostics (LBx), this goal is very ambitious because small tumors release only minute amounts of cells or cellular products (e.g., DNA, RNA, protein, metabolites) into the circulation. Thus, tests with a high sensitivity are required but increases in sensitivity are usually achieved on the expenses of reduced specificity which can lead to significant overdiagnosis leading to unnecessary stress for the individuals with a false-positive blood test and high costs for the health system. In PANCAID, we will therefore establish a blood test with high accuracy by analyzing large cohorts of patients with PDAC and its precursor lesions, individuals at risk to develop PDAC and appropriate age-matched control groups (healthy and non-cancer diseases frequent in the targeted population). Ambitious objectives of PANCAID include (1) establishment of a unique resource of blood samples of early PDAC and risk groups (WP1); (2) Establishment of a breakthrough blood test for early diagnosis of PDAC (WP2); (3) Identification of the best composite biomarker panel by integrating multimodal features in an AI-assisted computational analysis; (4) Analysis of the socio-economic impact of early PDAC diagnosis (WP4); and (5) Definition of the ethics parameters relevant to early PDAC detection (WP5). A robust multi-biomarker panel will be determined during the training period (year 1-3) and subsequently validated on bio-banked blood samples (year 4-5). Depending on the outcome of this comprehensive analysis, PANCAID will provide the design of a future prospective study for validation of the developed composite blood test in an international multi-center setting required to introduce LBx into screening programs for high-risk individuals. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores